Table 3.
Subgroup analysis of complete response rates by allocation factors
| Control group† (n = 154) | Study treatment group‡ (n = 151) | Difference between arms (95% CI) | Interaction test | |
|---|---|---|---|---|
| Age, n (%) | ||||
| Under 55 years | 13 (59.1) | 8 (33.3) | −25.8% (−53.7–2.1%) | 0.081 |
| 55 years or older | 85 (64.4) | 92 (72.4) | 8.1% (−3.2–19.3%) | |
| Sex, n (%) | ||||
| Male | 62 (71.3) | 65 (75.6) | 4.3% (−8.8–17.5%) | 0.500 |
| Female | 36 (53.7) | 35 (53.9) | 0.1% (−16.9–17.1%) | |
| Chemotherapy regimen, n (%) | ||||
| Oxaliplatin-based | 71 (63.4) | 76 (69.1) | 5.7% (−6.7–18.1%) | 0.351 |
| Irinotecan-based | 13 (65.0) | 14 (66.7) | 1.7% (−27.4–30.7%) | |
| Other | 14 (63.6) | 10 (50.0) | −13.6% (−43.4–16.1%) | |
†Control group: Palonosetron day 1+ dexamethasone days 1–3; ‡Study treatment group: Palonosetron day 1+ dexamethasone day 1. CI, confidence interval.